See related commentary by Busani and Girardis, <http://ccforum.com/content/16/4/143>

Introduction
============

Despite significant improvements in clinical management, including systematic multimodal approaches \[[@B1]\], severe forms of infections, such as severe sepsis and septic shock, are the leading causes of mortality in patients admitted to the intensive care unit (ICU) \[[@B2]-[@B4]\]. Over the last two decades, several promising therapeutic strategies designed to specifically target pathogen or host-related mediators involved in the septic process have failed to reduce mortality \[[@B5]-[@B7]\], and this failure is due, in part, to the heterogeneity of both microbial agents and host inflammatory responses \[[@B8]\]. Since therapeutic strategies should be adapted to each individual patient, the identification of patients who are at high risk of death and who might benefit most from early and aggressive treatment would represent a critical step toward such tailored management \[[@B9]\]. Serum biomarkers may assist clinicians in risk stratification and decision-making processes \[[@B10]\]. An ideal biomarker in patients with sepsis should improve early diagnosis and predict early deterioration toward organ failure and eventually death, thereby identifying patients requiring additional aggressive treatments \[[@B11]\]. Owing to a lack of specificity or sensitivity or both (for example, C-reactive protein (CRP) and procalcitonin (PCT) \[[@B10],[@B12]\]) or to a narrow time window of expression (for example, interleukin-6 (IL-6) and IL-8 \[[@B8]\]), currently used biomarkers do not fulfill such requirements. Therefore, further efforts are needed to identify novel sepsis biomarkers.

Pancreatic stone protein/regenerating protein (PSP/*reg*) is constitutively secreted by pancreatic acinar cells into pancreatic juice along with zymogens and is also secreted by subsets of intestinal and gastric cells \[[@B13]\]. Although its precise physiological roles remain only partly defined, it appears to have protective functions by promoting cellular proliferative responses during beta-cell regenerative processes and epithelial repair \[[@B13]\]. PSP/*reg*is upregulated during acute and chronic pancreatitis; in animals, its expression may be induced by stress conditions in the absence of any pancreatic inflammation. In a recent clinical study, serum concentrations of PSP/*reg*were found to be markedly elevated after trauma, and PSP/*reg*concentrations showed a close correlation with the severity of post-trauma infection \[[@B14]\]. Furthermore, PSP/*reg*was found to bind to polymorphonuclear cells and seemed to induce or maintain their activation or both; thus, PSP/*reg*might serve as an acute-phase protein \[[@B14]\].

We therefore hypothesized that PSP/*reg*concentration may represent a potential biomarker of sepsis-related inflammation. To address this hypothesis, we prospectively measured plasma concentrations of PSP/*reg*within 24 hours of ICU admission in 107 patients with clinically diagnosed forms of severe infections. (Some of the results of these studies have been reported in the form of an abstract \[[@B15]\].)

Materials and methods
=====================

Patient population
------------------

This study was performed between February 2008 and June 2010 in a 32-bed adult medico-surgical ICU of a community and referral university hospital. Patients who were at least 18 years old were evaluated within 24 hours of ICU admission for severe sepsis or septic shock. Owing to organizational constraints, inclusion was prospective but could not be strictly consecutive. The study was approved by the Institutional Review Board (Commission cantonale \[VD\] d\'éthique de la recherche sur l\'être humain, Lausanne, Switzerland). Written informed consent was obtained from patients or relatives. Infections, sepsis, severe sepsis, and septic shock were defined according to commonly used criteria \[[@B16]\] (Additional file [1](#S1){ref-type="supplementary-material"}). Patients were followed until death or discharge from the hospital. In-hospital mortality was the primary endpoint.

Data collection
---------------

In addition to recording clinical variables collected from the computerized information system (Metavision; IMDsoft, Tel Aviv, Israel), we recorded the age, sex, admission category, origin (home, emergency room, or ward), and McCabe score of each patient \[[@B17]\]. Severity of illness was evaluated on the first day in the ICU by using the Simplified Acute Physiology Score (SAPS) II \[[@B18]\] and III \[[@B19]\] and the Acute Physiology and Chronic Health Evaluation II (APACHE II) score \[[@B20]\]. Organ dysfunction was evaluated by the Sequential Organ Failure Assessment (SOFA) score \[[@B21]\]. Severe comorbidities were described by using definitions of the APACHE II score and SAPS II and III.

Measurement of plasma biomarker concentrations
----------------------------------------------

At the time of enrollment, heparinized plasma was obtained from each patient for measurements of biomarkers. (Detailed measurement protocols are presented in Additional file [1](#S1){ref-type="supplementary-material"}.) PSP/*reg*was quantified by using an isoform-specific enzyme-linked immunosorbent assay as described previously \[[@B14]\]. Briefly, plasma samples were incubated with plates precoated with guinea pig anti-PSP/*reg*antibody. Rabbit anti-PSP/*reg*was added and subsequently detected by phosphatase-conjugated anti-rabbit immunglobulin G. This assay had a detection limit of less than 0.1 ng/mL and an inter-plate variance of less than 10% \[[@B14]\].

Statistical analysis
--------------------

Continuous variables are reported as mean and standard deviation (SD) or medians and interquartile ranges (IQRs) as indicated. Categorical variables are reported as frequencies and percentages. Because the distributions of the biomarkers were skewed, continuous variables between severity of infection or between survivors and non-survivors were compared by using non-parametric two-sided Wilcoxon-Mann-Whitney rank sum tests. APACHE II, SAPS II and III, and SOFA scores are expressed as mean and SD.

Receiver operating characteristic (ROC) curves using concentrations of acute-phase proteins (CRP, PCT, and PSP/*reg*), pro-inflammatory cytokines (IL-6, IL-8, and IL-10), and acute severity scores (APACHE II and SAPS II and III) as independent variables and mortality as a dependent variable were computed first for the entire population and then specifically for patients with septic shock only. From these curves, we computed areas under the curve (AUCs) and 95% confidence intervals (CIs) to assess the discrimination ability of each marker for predictive purposes. Multiple logistic regression analysis and age-adjusted predicted hospital mortality (expressed as age-adjusted beta regression coefficients) were used to assess the relationship (for example, linearity and distribution) between biomarker concentrations and in-hospital mortality. Finally, we estimated the odds ratios (ORs) for mortality and trends across biomarker quartiles. All *P*values were two-sided, and statistical significance was set at a *P*value of less than 0.05. We used Stata (version 11.2; StataCorp LP, College Station, TX, USA) for data processing and analyses.

Results
=======

Patient characteristics
-----------------------

From February 2008 to June 2010, 177 patients were prospectively screened (Additional file [2](#S2){ref-type="supplementary-material"}, Figure S1); of these, 25 (14%) declined consent and 18 (10%) died before consent could be obtained. We included 107 patients: 33 (30%) with severe sepsis and 74 (70%) with septic shock (Table [1](#T1){ref-type="table"}). There were more males than females in each subgroup. Sixty-one (57%) and 46 (43%) patients presented with community-acquired and nosocomial infections, respectively. Over 75% of patients had pulmonary or abdominal infections, and high percentages were infected with *Streptococcus pneumoniae*(18.7%) or *Escherichia coli*(21.5%). The overall in-hospital mortality rates were 20.5%, 9% for patients with severe sepsis, and 25.7% for patients with septic shock. Most patients had at least one comorbid condition, but fewer than 14% had McCabe scores predicting rapidly fatal outcome.

###### 

Patient characteristics, by sepsis severity (*n*= 107)

  Patient characteristic                               All          Severe sepsis   Septic shock
  ---------------------------------------------------- ------------ --------------- --------------
  Demographics                                                                      
   Age in years, mean ± SD                             59 ± 17.5    55 ± 20         61 ± 16
   Male/Female                                         62/45        20/13           42/32
  Admission categories                                                              
   Medical                                             72 (67%)     24 (73%)        48 (65%)
   Scheduled surgery                                   4 (4%)       0 (0%)          4 (5%)
   Unscheduled surgery                                 31 (29%)     9 (27%)         22 (30%)
  Origin                                                                            
   Community (home/emergency room)                     61 (57%)     18 (54.5%)      43 (58.1%)
   Nosocomial (hospital transfer)                      46 (43%)     15 (45.5%)      31 (41.9%)
    Referral from other hospital                       20 (18.7%)   5 (15.2%)       15 (20.3%)
    Operating room                                     3 (2.8%)     1 (3%)          2 (2.7%)
    Ward                                               14 (13.1%)   6 (18.2%)       8 (10.8%)
    Intermediate care                                  9 (8.4%)     3 (9.1%)        6 (8.1%)
  Severe comorbidities                                                              
   Chronic obstructive pulmonary disease               17 (15.8%)   5 (15.1%)       12 (16.2%)
   Cardiac insufficiency                               16 (15%)     2 (6%)          14 (18.9%)
   Cirrhosis                                           8 (7.5%)     1 (3%)          7 (9.5%)
   End-stage renal disease                             15 (14%)     3 (9%)          12 (16.2%)
   Immunodeficiency^a^                                 13 (12.1%)   2 (6%)          11 (14.9%)
   Insulin-dependent diabetes                          6 (5.6%)     1 (3%)          5 (6.7%)
  Score, mean ± SD                                                                  
   APACHE II                                           30 ± 8       27 ± 86         31 ± 8
   SAPS II                                             71 ± 17      65 ± 16         74 ± 17
   SAPS III                                            76 ± 18      67 ± 21         80 ± 15
   SOFA (day 1)                                        11 ± 3       11 ± 3          11 ± 3
  McCabe score                                                                      
   Non-fatal                                           63 (59%)     22 (66.6%)      41 (55%)
   Ultimately fatal (\< 5 years)                       30 (28%)     7 (21.2%)       23 (31%)
   Rapid fatal (\< 6 months)                           14 (13%)     4 (12.2%)       10 (14%)
  Infection sites                                                                   
   Pulmonary                                           37 (34.5%)   14 (42.4%)      23 (31%)
   Abdominal                                           38 (36%)     7 (21.2%)       31 (41.9%)
   Bloodstream                                         7 (6.5%)     4 (12.1%)       3 (4.1%)
   CNS and ENT                                         5 (4.6%)     2 (6.1%)        3 (4.1%)
   Urinary tract                                       5 (4.6%)     2 (6.1%)        3 (4.1%)
   Soft tissues                                        13 (12%)     4 (12.1%)       9 (12.1%)
   Miscellaneous                                       2 (1.8%)     0 (0%)          2 (2.7%)
  Microbiology                                                                      
   Gram-positive (number of positive blood cultures)   41 (38.3%)   17 (51.5%)      24 (32.4%)
    *Staphylococcus aureus*(8)                         8 (7.5%)     5 (15.1%)       3 (4.1%)
    *Streptococcus pyogenes*(2)                        10 (9.3%)    2 (6.1%)        8 (10.8%)
    *Streptococcus pneumoniae*(8)                      20 (18.7%)   8 (24.2%)       12 (16.1%)
    Other (2)                                          3 (2.8%)     2 (6.1%)        1 (1.4%)
   Gram-negative                                       45 (42%)     13 (39.4%)      32 (43.2%)
    *Escherichia coli*(14)                             23 (21.5%)   5 (15.2%)       18 (24.3%)
    Other Enterobacteriacae (5)                        7 (6.5%)     1 (3.05%)       6 (8.1%)
    *Pseudomonas aeruginosa*(5)                        6 (5.6%)     3 (9.05%)       3 (4.1%)
    Other (5)                                          9 (8.4%)     4 (12.1%)       5 (6.7%)
   Fungi                                               3 (2.8%)     0 (0%)          3 (4.1%)
    *Candida albicans*(1)                              1 (1%)       0 (0%)          1 (1.4%)
    Other (0)                                          2 (1.8%)     0 (0%)          2 (2.7%)
   H1N1                                                1 (1%)       0 (0%)          1 (1.4%)
   Undocumented                                        17 (15.9%)   3 (9.1%)        14 (18.9%)
  Outcome                                                                           
   Hospital mortality                                  22 (20.6%)   3 (9%)          19 (25.7%)

Values are presented as numbers (percentages) of patients unless indicated otherwise. ^a^HIV, solid organ transplant recipients, hematological malignancies, chronic use of more than 30 mg per day prednisone equivalents. APACHE II, Acute Physiology and Chronic Health Evaluation II; CNS, central nervous system; ENT, ear, nose, and throat; SAPS, Simplified Acute Physiology Score; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.

Plasma levels of CRP, PCT, PSP/*reg*, and inflammatory cytokines in patients with severe sepsis and septic shock
----------------------------------------------------------------------------------------------------------------

Plasma concentrations of the various biomarkers in relation to the severity of infection (severe sepsis or septic shock) are presented in Table [2](#T2){ref-type="table"} and in Figure S2 of Additional file [3](#S3){ref-type="supplementary-material"}. In comparison with the concentrations of CRP, those of the acute-phase proteins PCT and PSP/*reg*and the pro-inflammatory cytokines IL-6 and IL-8 were significantly higher in patients with septic shock than in patients with severe sepsis, and the median PSP/*reg*concentration was about five times higher in patients with septic shock (343.5 ng/L) than in patients with severe sepsis (73.5 ng/L). As expected, the acute severity scores (APACHE II and SAPS II and III) were significantly higher in patients with septic shock than in those with severe sepsis.

###### 

Plasma concentrations of biomarkers and severity scores, by sepsis severity

  Biomarker or severity scoring system   All (*n*= 107)   Severe sepsis (*n*= 33)   Septic shock (*n*= 74)                                     
  -------------------------------------- ---------------- ------------------------- ------------------------ ---------- ---------- ----------- -----------
  Acute-phase proteins                                                                                                                         
   CRP, mg/L                             253.5            155.5                     218                      152        266        158         0.35
   PCT, ng/mL                            25.12            48.98                     11.96                    20.94      39.25      49.99       \< 0.0001
   PSP/*reg*, ng/mL                      241.25           399.00                    73.5                     180.25     343.5      369         \< 0.0001
  Cytokines                                                                                                                                    
   TNF-α, pg/ml                          2.47             7.07                      1.93                     7.07       2.41       6.97        0.86
   IL-1β, pg/mL                          6.43             21.04                     1.96                     15.53      8.175      24.54       0.21
   IL-6, pg/mL                           1,173.28         6,749.6                   544.07                   1,237.48   1,755.34   14,514.13   0.004
   IL-8, pg/mL                           438.95           1,804.67                  184.15                   408.72     681.775    3,273.42    0.0001
   IL-10, pg/mL                          149.37           672.82                    76.24                    239.67     199.94     706.22      0.045
  Other                                                                                                                                        
   Leukocytes, G/L                       13.5             14.2                      13.5                     5.5        13.3       17.1        0.28
   APACHE II                             28               14                        26                       14         29         14          0.04
   SAPS II                               69               26                        62                       29         71         27          0.02
   SAPS III                              76               27                        69                       28         79.5       25          0.001
   SOFA                                  11               4                         10                       5          11         5           0.35

APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C-reactive protein; IL, interleukin; IQR, interquartile range; PCT, procalcitonin; PSP/*reg*, pancreatic stone protein/regenerating protein; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; TNF-α, tumor necrosis factor-alpha.

PSP/*reg*was further measured in the plasma of burned patients who were previously admitted to our ICU and in whom trace element supplementation resulted in improved clinical outcome, including fewer pulmonary infections and better wound healing \[[@B22]\]. In these 20 patients with severe non-infectious inflammation (mean age of 43 ± 16 years, mean total surface body area burned of 45% ± 22%, and median SAPS II of 32 and IQR of 14), the median PSP/*reg*within the first 24 hours of admission was 13.0 ng/mL (IQR of 4.8). Figure S3 of Additional file [4](#S4){ref-type="supplementary-material"} displays the individual values of PSP/*reg*in these patients compared with those with severe sepsis and septic shock.

Association between plasma levels of CRP, PCT, PSP/*reg*, and inflammatory cytokines and in-hospital mortality
--------------------------------------------------------------------------------------------------------------

We assessed the relationship between the plasma concentrations of CRP, PCT, and PSP/*reg*; the concentrations of inflammatory cytokines; the number of leukocytes; severity scores (APACHE II, SAPS II and III, and SOFA); and in-hospital mortality in patients with severe sepsis or septic shock (Table [3](#T3){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}, Table S1). Overall, regardless of severity, PSP/*reg*concentrations and SAPS III scores were the only variables that differed significantly between survivors and non-survivors (Table [3](#T3){ref-type="table"}). Despite their association with severity, IL-6, IL-8, PCT, APACHE II, and SAPS II were not associated with mortality. Among patients with septic shock (Additional file [1](#S1){ref-type="supplementary-material"}, Table S1), PSP/*reg*remained the only biomarker significantly associated with mortality (*P*= 0.049).

###### 

Plasma concentrations of biomarkers and severity scores, by survival status

  Biomarker or severity scoring system   All (*n*= 107)                                   
  -------------------------------------- ---------------- ----------- -------- ---------- ------
  Acute-phase proteins                                                                    
   CRP, mg/L                             203              188         266      154        0.21
   PCT, ng/mL                            17.485           51.75       26.22    44.75      0.57
   PSP/*reg*, ng/mL                      397              435.9       216.1    379        0.02
  Cytokines                                                                               
   TNF-α, pg/ml                          2.655            10.36       2.35     6.73       0.46
   IL-1β, pg/mL                          0.795            34.02       7.6      20.41      0.46
   IL-6, pg/mL                           2,415.58         16,219.42   790.53   6,467.74   0.16
   IL-8, pg/mL                           757.775          10,597.73   414.88   1,597.6    0.11
   IL-10, pg/mL                          416.18           1393.6      136.76   494.89     0.17
  Other                                                                                   
   Leukocytes, G/L                       13.85            14.45       13.4     14.2       0.27
   APACHE II                             32               12          27       13         0.4
   SAPS II                               71.5             26          68       27         0.52
   SAPS III                              87.5             27          74       25         0.01
   SOFA                                  11               6           11       4          0.9

APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C-reactive protein; IL, interleukin; IQR, interquartile range; PCT, procalcitonin; PSP/*reg*, pancreatic stone protein/regenerating protein; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; TNF-α, tumor necrosis factor-alpha.

Biomarkers and severity scores as predictors of in-hospital mortality
---------------------------------------------------------------------

We used AUC analysis to further explore the capacity of each parameter to predict mortality at ICU admission (Figure [1](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}, Table S2) within our particular population of patients admitted with a diagnosis of severe sepsis or septic shock. ROCs were computed for the entire patient cohort (Figure [1a](#F1){ref-type="fig"}) and for patients with septic shock (Figure [1b](#F1){ref-type="fig"}). When applied to the whole population, PSP/*reg*, IL-8, and IL-6 yielded the highest discriminative value with AUCs (95% CIs) of 0.65 (0.51 to 0.80), 0.61 (0.43 to 0.77), and 0.59 (0.44 to 0.75), respectively. In contrast, the AUCs (95% CIs) of CRP and PCT were 0.44 (0.29 to 0.60) and 0.46 (0.29 to 0.61), respectively (Figure [1a](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}, Table S2). Similar patterns and AUC values were observed when the analysis was restricted to patients with septic shock (Figure [1b](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}, Table S2).

![**Receiver operating characteristic (ROC) curves for the entire patient cohort (a) and for patients with septic shock (b)**. Areas under the curve (AUCs) were determined for acute-phase proteins, pro-inflammatory cytokines, and severity scores. APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C-reactive protein; IL, interleukin; PCT, procalcitonin; PSP, pancreatic stone protein; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.](cc11406-1){#F1}

PSP/*reg*showed a more uniform and linear distribution than other biomarkers throughout the range of probability of in-hospital mortality (Figure [2a, b](#F2){ref-type="fig"}). Only seven patients with septic shock (9.5%) presented with IL-6 concentrations in the three highest quartiles in comparison with 20 (27%) for PSP/*reg*(Figure [2b](#F2){ref-type="fig"}).

![**Probability of in-hospital mortality upon admission among the entire patient cohort (a) and patients with septic shock (b)**. Probabilities are according to their concentrations of plasma pancreatic stone protein/regenerating protein (PSP/*reg*) (crosses), interleukin-6 (IL-6) (open circles), and procalcitonin (PCT) (closed circles). Gradients of grey correspond to quartiles of biomarker concentrations.](cc11406-2){#F2}

The age-adjusted beta regression coefficients - that is, the change in probability of in-hospital mortality per standard unit (one SD) change in biomarker concentration - were 0.16 (SD of 0.07) per 100 ng/mL increase of PSP/*reg*(*P*= 0.03), 0.17 (SD of 0.10) per 50 ng/mL increase of IL-6 (*P*= 0.08), and -0.00076 (SD of 0.0587) per 10 ng/mL increase of PCT (*P*= 0.99). When restricted to patients with septic shock, the age-adjusted beta regression coefficients were 0.16 (SD of 0.08) per 100 ng/mL increase of PSP/*reg*(*P*= 0.048), 0.15 (SD of 0.10) per 50 ng/mL increase of IL-6 (*P*= 0.15), and -0.0167 (SD of 0.062) per 10 ng/mL increase of PCT (*P*= 0.79).

Moreover, in contrast to IL-6 and PCT, the age-adjusted ORs (95% CIs) of mortality among patients with septic shock increased continuously across PSP/*reg*quartiles: PSP/*reg*OR 1.0 \[reference group\], 1.5 (0.19 to 10.0), 5.1 (0.8 to 32.0), and 6.4 (0.96 to 42.0), respectively (test for trend *P*= 0.02). For IL-6 quartiles, the age-adjusted ORs (95% CIs) for mortality among patients with septic shock were 1.0 \[reference group\], 2.0 (0.36 to 10.0), 1.3 (0.23 to 7.5), and 2.4 (0.45 to 12.0), respectively (test for trend *P*= 0.41), whereas, for PCT, the corresponding values were 1.0 \[reference group\], 0.4 (0.7 to 2.0), 0.7 (0.16 to 3.1), and 0.4 (0.08 to 1.9), respectively (test for trend *P*= 0.35).

Discussion
==========

Our results suggest that PSP/*reg*, a novel acute-phase protein, measured within 24 hours of ICU admission, may predict the risk of mortality in patients with severe sepsis and septic shock. PSP/*reg*was identified in patients with pancreatitis and further associated with islet regeneration \[[@B13],[@B23]\]. The findings that its expression was not restricted to the pancreas \[[@B24],[@B25]\] and that it can be induced by stress in animals \[[@B26]\] opened the way to investigate its role as a potential acute-phase protein. A recent study in 83 trauma patients reported that PSP/*reg*concentrations were 15-fold higher from baseline (5 to 15 ng/mL) in patients developing septic complications \[[@B14]\].

Our results suggest that PSP/*reg*, measured within 24 hours of ICU admission, may be used as a biomarker to identify septic patients at highest risk of death. PSP/*reg*performed better than CRP and PCT, which are widely used to diagnose infection but which, owing to their poor accuracy in this indication, should not be used to predict disease outcome \[[@B10],[@B12],[@B27],[@B28]\]. A similar observation was recently reported in a cohort of 101 patients with ventilator-associated pneumonia \[[@B29]\]. In this cohort, PSP/*reg*measured after 7 days of mechanical ventilation predicted subsequent organ failure development and, eventually, outcome. A major advantage of PSP/*reg*over the currently available predictors of disease evolution, such as cytokines, may be its presence in the plasma of all septic patients at the time of ICU admission. This sharply contrasts with the pro-inflammatory cytokines tumor necrosis factor-alpha, IL-1, and IL-6, which showed very good predictive values in dedicated trials \[[@B30],[@B31]\] but whose use in daily life was finally hampered by their short window of expression in plasma, making them difficult to interpret at the bedside in a population of patients in whom the time between the onset of sepsis and the blood test cannot be standardized \[[@B32]\].

The strength of our study is that it is representative of the usual population of patients admitted to a mixed ICU. Inclusion criteria were simple, making the setting correspond to what any clinician could encounter in his or her daily practice, increasing the chances of PSP/*reg*measurement implementation at the bedside to predict patient outcome. The small number of patients may explain the absence of a correlation of APACHE II or SAPS II with mortality in a cohort of patients with severe infections \[[@B33]\]. In this context, the strong association of PSP/*reg*with mortality might be viewed as indirect evidence of its better specificity for sepsis. The fact that stratification of patients with sepsis could occur within 24 hours of admission would eventually exclude from stratification most patients without a clear diagnosis of sepsis (this strategy resulted in a low number of non-documented infections in our study) as well as those dying rapidly despite resuscitation and for whom very early evaluation of prognosis (\< 18 hours) would probably not result in a different initial management \[[@B1]\].

This single-center study also has several limitations. First, since 18 (10%) patients died before consent could be obtained, selection bias cannot be excluded. This may also have contributed to the lower mortality rate of our patients with septic shock compared with rates reported earlier \[[@B2]-[@B4]\]. Second, owing to organizational constraints, patient recruitment was restricted to periods when co-investigators worked as attending physicians. Third, since the purpose of the study was to explore the accuracy of PSP/*reg*compared with that of other commonly used or studied predictors (such as pro-inflammatory cytokines) in a homogenous population of patients with a definite diagnosis of sepsis at the time of ICU admission and not between populations of septic and non-septic patients, patients without sepsis were not included. This may have resulted in an apparently modest absolute predicting power (ROC of 0.65). Finally, owing to the relatively small number of patients, these results require further validation in a larger and preferentially multicentric cohort of patients with sepsis.

Though preliminary, our data still suggest that PSP/*reg*determination could be useful in the stratification of patients with septic shock. After initial resuscitation, PSP/*reg*blood levels that are measured within 24 hours of ICU admission may help to detect patients at high risk of death and to reduce the number of those susceptible to receive new and costly adjunctive treatments, such as specific immunotherapy \[[@B34]\], anti-cytokines \[[@B35]\], or extra-corporeal lipopolysaccharide removal \[[@B36]\].

Conclusions
===========

We conclude that a single measurement of PSP/*reg*concentration within 24 hours of ICU admission stratifies patients with sepsis according to severity of infection and risk of death. If our findings are confirmed by further studies, this promising biomarker may help physicians to tailor treatments to individual patients according to risk of death.

Key messages
============

• Commonly used biomarkers, such as C-reactive protein and procalcitonin, are insufficiently sensitive or specific to stratify patients with sepsis.

• Pancreatic stone protein/regenerating protein (PSP/*reg*) is an accurate biomarker to stratify septic patients admitted to intensive care units (ICUs).

• PSP/*reg*blood measurement within 24 hours of ICU admission predicts risk of death more accurately than procalcitonin and pro-inflammatory cytokines.

• PSP/*reg*may help to identify, among all patients admitted for sepsis, those most susceptible to benefit from aggressive management.
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**Figure S1: Study flow chart**.
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###### Additional file 3

**Figure S2: Plasma concentrations and medians (dashed lines) of acute phase proteins (Panel A) and pro-inflammatory cytokines (Panel B) within 24 h of ICU admission among 107 patients admitted for severe sepsis (*n*= 33) and septic shock (*n*= 74)**.
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**Figure S3: Plasma concentrations of PSP/reg in patients admitted for severe burns, for severe sepsis and septic shock, respectively (Box plot: median, 25th and 75th percentiles, min, max**. Diamond: mean value).
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